Telomir Pharmaceuticals, Inc.
TELO
$4.66
-$0.375-7.46%
| Weiss Ratings | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 12.71% | |||
| 30-Day Total Return | 2.99% | |||
| 60-Day Total Return | -10.48% | |||
| 90-Day Total Return | 14.66% | |||
| Year to Date Total Return | 14.37% | |||
| 1-Year Total Return | -28.49% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -46.43% | |||
| 52-Week Low % Change | 61.74% | |||
| Price | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.39 | |||
| 52-Week Low Price | $3.11 | |||
| 52-Week Low Price (Date) | Aug 02, 2024 | |||
| 52-Week High Price (Date) | Apr 16, 2024 | |||
| Valuation | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 149.71M | |||
| Enterprise Value | 148.53M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.57 | |||
| Earnings Per Share Growth | 18.96% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 232.87 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $4.66 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -12.07 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 29.66M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 786 396 6723 | |||
| Address | 100 SE 2nd Street Miami, FL 33131 | |||
| Website | telomirpharma.com | |||
| Country | United States | |||
| Year Founded | 2021 | |||
| Profitability | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -252.19% | |||
| Return on Equity | -- | |||
| Income Statement | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -12.30M | |||
| Net Income (TTM) | -16.59M | |||
| Net Income Avl. to Common (TTM) | -16.59M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 68.93% | |||
| EPS Diluted (TTM) | -0.57 | |||
| EPS Diluted Growth (Q YOY) | 71.62% | |||
| Balance Sheet | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.27M | |||
| Cash Per Share (Q) | $0.04 | |||
| Total Current Assets (Q) | 1.32M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 643.00K | |||
| Current Ratio (Q) | 1.944 | |||
| Book Value Per Share (Q) | $0.02 | |||
| Total Assets (Q) | 1.32M | |||
| Total Current Liabilities (Q) | 681.00K | |||
| Total Debt (Q) | 93.40K | |||
| Total Liabilities (Q) | 681.00K | |||
| Total Common Equity (Q) | 643.00K | |||
| Cash Flow | TELO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 6.34M | |||
| Net Change in Cash (TTM) | 1.26M | |||
| Levered Free Cash Flow (TTM) | 1.06M | |||
| Cash from Operations (TTM) | -5.07M | |||
